Kathryn E. Falberg, Director at Arcus Biosciences, Inc. (RCUS), bought 20,000 shares at $8.49 ($164K) on 2019-06-12, disclosed to the SEC on 2019-06-13.
Open-market purchase of $164k RCUS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.90 | 10,000 | $79K | 48.2% |
| 2 | $8.49 | 10,000 | $85K | 51.8% |
| Total | $8.20 avg | 20,000 | $164K | 100% |
| Filing → |
| TTD | SELL | 2024-03-12 | $16.9M | — | Filing → |
| NUVB | BUY | 2022-12-05 | $789K | — | Filing → |
| TTD | SELL | 2021-11-23 | $32.5M | — | Filing → |